GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Accustem Sciences Inc (OTCPK:ACUT) » Definitions » Equity-to-Asset

ACUT (Accustem Sciences) Equity-to-Asset : -30.71 (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Accustem Sciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Accustem Sciences's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $-3.19 Mil. Accustem Sciences's Total Assets for the quarter that ended in Sep. 2024 was $0.10 Mil.

The historical rank and industry rank for Accustem Sciences's Equity-to-Asset or its related term are showing as below:

ACUT' s Equity-to-Asset Range Over the Past 10 Years
Min: -51.37   Med: -11.53   Max: -0.15
Current: -30.71

During the past 2 years, the highest Equity to Asset Ratio of Accustem Sciences was -0.15. The lowest was -51.37. And the median was -11.53.

ACUT's Equity-to-Asset is ranked worse than
98.81% of 1508 companies
in the Biotechnology industry
Industry Median: 0.67 vs ACUT: -30.71

Accustem Sciences Equity-to-Asset Historical Data

The historical data trend for Accustem Sciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accustem Sciences Equity-to-Asset Chart

Accustem Sciences Annual Data
Trend Dec22 Dec23
Equity-to-Asset
-0.15 -15.76

Accustem Sciences Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -7.31 -15.76 -51.37 -20.60 -30.71

Competitive Comparison of Accustem Sciences's Equity-to-Asset

For the Biotechnology subindustry, Accustem Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accustem Sciences's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Accustem Sciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Accustem Sciences's Equity-to-Asset falls into.



Accustem Sciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Accustem Sciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-2.112/0.134
=

Accustem Sciences's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=-3.194/0.104
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accustem Sciences  (OTCPK:ACUT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Accustem Sciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Accustem Sciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Accustem Sciences Business Description

Traded in Other Exchanges
N/A
Address
5 Penn Plaza, Suite 1954, Floor 19th, New York, NY, USA, 10001
Accustem Sciences Inc is a life sciences company that focuses on enhancing cancer patient outcomes through diagnostic, pharmaceutical, and medical device products. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services. Operations span New York, NY, and London, UK.